• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Allergan profits slimmer despite plumper sales | Earnings roundup

Allergan profits slimmer despite plumper sales | Earnings roundup

May 5, 2011 By MassDevice staff

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Allergan profits shrink despite 10 percent revenue bump
Allergan Inc. (NYSE:AGN) posted profits of $158.3 million, or 51 cents per diluted share, on sales of $1.27 billion during the three months ended March 31. That compares with profits of $167.9 million, or 55 cents per diluted share, on sales of $1.15 billion during the same period last year.
Read more

Volcano Corp. puffs out of the red
Volcano Corp. (NSDQ:VOLC) posted net earnings of $1.2 million, or 2 cents per diluted share, on revenue of $81.0 million during the three months ended March 31. That compares with losses of $4.0 million, or 8 cents per diluted share, on revenue of $66.6 million during the same period last year.
Read more

NxStage boasts record Q1 sales
NxStage Medical Inc. (NSDQ:NXTM) reported losses of $6.0 million, or 11 cents per diluted share, on sales of $50.6 during the three months ended March 31. That compares with net earnings of $9.0 million, or 19 cents per diluted share, on sales of $40.4 million during the same period last year.
Read more

BioClinica clings to profitability
BioClinica Inc. (NSDQ:BIOC) reported a profit of $351,000, or 2 cents per diluted share, on revenue of $19.7 million during the three months ended March 31. That compares with a profits of $711,000, or 5 cents per diluted share, on revenue of $18.1 million during the same period last year.
Read more

Anika Therapeutics income halves
Anika Therapeutics Inc. (NSDQ:ANIK) posted profit of $324,412, or 3 cents per diluted share, on sales of $11.7 million during the three months ended March 31. That compares with profits of $714,280, or 6 cents per diluted share, on sales of $12.5 million during the same period last year.
Read more

Orthovita losses remain unchanged, but sales dip
Orthovita Inc. (NSDQ:VITA) posted losses of $1.2 million, or 2 cents per diluted share, on revenue of $23.8 million during the three months ended March 31. That compares a loss of $1.2 million, or 2 cents per diluted share, on revenue of $24.1 million during the same period last year.
Read more

Cardiovascular Systems cuts losses after sales jump 22 percent
Cardiovascular Systems Inc. (NSDQ:CSII) reported a loss of $2.4 million, or 15 cents per diluted share, on sales of $20.2 million during the three months ended March 31. That compares with a loss of $6.5 million, or 44 cents per diluted share, on sales of $16.5 million during the same period last year.

Cardiogenesis losses widen as sales dip
Cardiogenesis Corp. (OTC:CGCP) posted a loss of $433,000, or 1 cent per diluted share, on sales of $3.1 million during the three months ended March 31. That compares with a loss of $18,000, or 0 cents per diluted share, on sales of $3.2 million during the same period last year.
Read more

AtriCure losses ease on improved sales
AtriCure Inc. (NYSE:ATRC) posted a loss of $1.3 million, or 8 cents per diluted share, on revenue of $15.6 million during the three months ended March 31. That compares with losses of $2.0 million, or 13 cents per diluted share, on revenue of $14.0 million during the same period last year.
Read more

Fresenius profits rise on increased sales
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported profits of $249.1 million, or 73 cents per share, on revenue of $3.04 billion during the three months ended March 31. That compares with profits of $230.2 million, or 70 cents per share, on revenue of $2.88 billion during the same period last year.
Read more

Dehaier profits halve despite revenue increase
Dehaier Medical Systems Ltd. (NSDQ:DHRM) posted profits of $209,744, or 4 cents per diluted share, on sales of $3.0 million during the three months ended March 31. That compares with a profit of $533,972, or 17 cents per diluted share, on sales of $2.6 million during the same period last year.
Read more

Artimplant losses ease as sales rise
Artimplant AB (STO:ARTIB) reported losses of SEK 3.9 million, or SEK 0.03 per diluted share, on revenue of SEK 5.4 million during the three months ended March 31. That compares with losses of SEK 4.7 million, or SEK 0.08 per diluted share, on revenue of SEK 4.8 million during the same period last year.
Read more

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: Allergan, Anika Therapeutics Inc., AtriCure Inc., BioClinica Inc., Cardiogenesis Corp., Cardiovascular Systems Inc., Dehaier Medical Systems Ltd., Fresenius, NxStage Medical Inc., Orthovita Inc., Q1, Volcano Corp.

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy